Application of PNA and LNA oligomers to chemotherapy

A. N. Elayadi, D. R. Corey

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

Peptide nucleic acid (PNA) and locked nucleic acid (LNA) oligomers bind to complementary sequences with extremely high affinity. This high-affinity binding supports the hypothesis that they have advantages for targeting cellular nucleic acids and provide a better route for the development of oligonucleotide-based antiproliferative drugs. This article reviews the properties of PNA and LNA oligomers and describes the challenges that confront their application to cancer therapy.

Original languageEnglish (US)
Pages (from-to)558-561
Number of pages4
JournalCurrent Opinion in Investigational Drugs
Volume2
Issue number4
StatePublished - 2001

Fingerprint

Peptide Nucleic Acids
Drug Therapy
Oligonucleotides
Nucleic Acids
Pharmaceutical Preparations
Neoplasms
locked nucleic acid
Therapeutics

Keywords

  • Antisense
  • Bridged nucleic acid
  • Hybridization
  • Locked nucleic acid
  • Oligonucleotide
  • Peptide nucleic acid
  • Telomerase

ASJC Scopus subject areas

  • Pharmacology

Cite this

Application of PNA and LNA oligomers to chemotherapy. / Elayadi, A. N.; Corey, D. R.

In: Current Opinion in Investigational Drugs, Vol. 2, No. 4, 2001, p. 558-561.

Research output: Contribution to journalArticle

@article{4983529027374ed286a00a53a285ea72,
title = "Application of PNA and LNA oligomers to chemotherapy",
abstract = "Peptide nucleic acid (PNA) and locked nucleic acid (LNA) oligomers bind to complementary sequences with extremely high affinity. This high-affinity binding supports the hypothesis that they have advantages for targeting cellular nucleic acids and provide a better route for the development of oligonucleotide-based antiproliferative drugs. This article reviews the properties of PNA and LNA oligomers and describes the challenges that confront their application to cancer therapy.",
keywords = "Antisense, Bridged nucleic acid, Hybridization, Locked nucleic acid, Oligonucleotide, Peptide nucleic acid, Telomerase",
author = "Elayadi, {A. N.} and Corey, {D. R.}",
year = "2001",
language = "English (US)",
volume = "2",
pages = "558--561",
journal = "Current Opinion in Investigational Drugs",
issn = "1354-3784",
publisher = "Informa Healthcare",
number = "4",

}

TY - JOUR

T1 - Application of PNA and LNA oligomers to chemotherapy

AU - Elayadi, A. N.

AU - Corey, D. R.

PY - 2001

Y1 - 2001

N2 - Peptide nucleic acid (PNA) and locked nucleic acid (LNA) oligomers bind to complementary sequences with extremely high affinity. This high-affinity binding supports the hypothesis that they have advantages for targeting cellular nucleic acids and provide a better route for the development of oligonucleotide-based antiproliferative drugs. This article reviews the properties of PNA and LNA oligomers and describes the challenges that confront their application to cancer therapy.

AB - Peptide nucleic acid (PNA) and locked nucleic acid (LNA) oligomers bind to complementary sequences with extremely high affinity. This high-affinity binding supports the hypothesis that they have advantages for targeting cellular nucleic acids and provide a better route for the development of oligonucleotide-based antiproliferative drugs. This article reviews the properties of PNA and LNA oligomers and describes the challenges that confront their application to cancer therapy.

KW - Antisense

KW - Bridged nucleic acid

KW - Hybridization

KW - Locked nucleic acid

KW - Oligonucleotide

KW - Peptide nucleic acid

KW - Telomerase

UR - http://www.scopus.com/inward/record.url?scp=0035048016&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035048016&partnerID=8YFLogxK

M3 - Article

VL - 2

SP - 558

EP - 561

JO - Current Opinion in Investigational Drugs

JF - Current Opinion in Investigational Drugs

SN - 1354-3784

IS - 4

ER -